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Regulatory T (T reg) cells are key mediators of 
peripheral tolerance that actively suppress effec-
tor T (T eff) cells and inhibit immune-mediated 
tissue damage (Kronenberg and Rudensky, 2005;   
Sakaguchi  et  al.,  2008;  Tang  and  Bluestone, 
2008). T reg cells can be divided into naturally 
occurring T reg (nT reg) and induced T reg (iT 
reg) cells. nT reg cells develop in the thymus,   
express the cardinal transcription factor forkhead 
box p3 (Foxp3; Fontenot et al., 2003; Hori 
et al., 2003), have high levels of CD25, and have 
a TCR repertoire biased toward self-antigens. 
In contrast, iT reg cells develop in the periph-
ery. In the presence of TGF-, naive CD4+ T 
cells are induced to express Foxp3 and are con-
verted toward an iT reg cell fate (Chen et al., 
2003; Fantini et al., 2004; Coombes et al., 2007; 
Rubtsov and Rudensky, 2007). These TGF-–
induced T reg cells, like nT reg cells, express 
high levels of CD25, CTLA-4, and GITR   
(glucocorticoid-induced TNF receptor), require 
prior stimulation for T reg cell activity, and po-
tently suppress T eff cells (Lohr et al., 2006). 
Programmed death (PD) 1 receptor (CD279) 
and  its  ligand  PD–ligand  (PD-L)  1  (B7-H1; 
CD274) are also highly expressed on T reg cells, 
but whether the PD-1–PD-L pathway plays a 
role in expansion or function of T reg cells is 
not  yet  clear  (Baecher-Allan  et  al.,  2003; 
Krupnick et al., 2005).
The pathway consisting of the receptor PD-1 
and  its  ligands,  PD-L1  and  PD-L2  (B7-DC; 
CD273), is a newer pathway in the B7-CD28 
family that regulates the balance between stimu-
latory and inhibitory signals needed for effective 
CORRESPONDENCE  
Arlene H. Sharpe: 
arlene_sharpe@hms.harvard.edu
Abbreviations used: Foxp3, 
forkhead box p3; iT reg, in-
duced T reg; MFI, mean fluo-
rescence intensity; nT reg, 
naturally occurring T reg; PD, 
programmed death; PD-L, PD-
ligand; T eff, effector T; T reg, 
regulatory T.
PD-L1 regulates the development, 
maintenance, and function of induced 
regulatory T cells
Loise M. Francisco,1,2  Victor H. Salinas,4 Keturah E. Brown,1  Vijay K.  Vanguri,1,2 
Gordon J. Freeman,5  Vijay K. Kuchroo,3 and Arlene H. Sharpe1,2
1Department of Pathology, Harvard Medical School, Boston, MA 02115
2Department of Pathology and 3Center for Neurological Diseases, Brigham and Women’s Hospital, Harvard Medical  
School, Boston, MA 02115
4Harvard University, Cambridge, MA 02138
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115
Both the programmed death (PD) 1–PD-ligand (PD-L) pathway and regulatory T (T reg) 
cells are instrumental to the maintenance of peripheral tolerance. We demonstrate that 
PD-L1 has a pivotal role in regulating induced T reg (iT reg) cell development and sustaining 
iT reg cell function. PD-L1/ antigen-presenting cells minimally convert naive CD4 T cells 
to iT reg cells, showing the essential role of PD-L1 for iT reg cell induction. PD-L1–coated 
beads induce iT reg cells in vitro, indicating that PD-L1 itself regulates iT reg cell develop-
ment. Furthermore, PD-L1 enhances and sustains Foxp3 expression and the suppressive  
function of iT reg cells. The obligatory role for PD-L1 in controlling iT reg cell development 
and function in vivo is illustrated by a marked reduction in iT reg cell conversion and rapid 
onset of a fatal inflammatory phenotype in PD-L1/PD-L2/ Rag/ recipients of naive 
CD4 T cells. PD-L1 iT reg cell development is mediated through the down-regulation of 
phospho-Akt, mTOR, S6, and ERK2 and concomitant with the up-regulation of PTEN, all 
key signaling molecules which are critical for iT reg cell development. Thus, PD-L1 can 
inhibit T cell responses by promoting both the induction and maintenance of iT reg cells. 
These studies define a novel mechanism for iT reg cell development and function, as well  
as a new strategy for controlling T reg cell plasticity.
© 2009 Francisco et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Figure 1.  PD-L1 mediates Foxp3+ iT reg cell development. (A and B) Development of Foxp3+ iT reg cells was assessed by flow cytometric analysis  
of Foxp3-GFP expression after co-culture of naive CD4+CD62L+Foxp3.GFP T cells with anti-CD3 and irradiated WT or PD-L1/ APCs plus the indicated 
range of TGF- concentrations for 3 d (A) or PD-L1–Ig or control Ig (human IgG1)–coupled beads (B). One representative experiment of at least three 
similar experiments is shown. (C) Analysis of Foxp3-GFP expression after culture of naive CD4+CD62L+Foxp3.GFP T cells with PD-L1–Ig beads and over  JEM VOL. 206, December 21, 2009 
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the indicated range of TGF- concentrations. *, P < 0.001 for PD-L1 bead comparing 0 ng/ml TGF- versus 0.5–8 ng/ml; **, P < 0.001 comparing PD-L1 
bead versus control bead at 0.5 ng/ml TGF-. Data represent the mean ± SD and are representative of at least four independent experiments. (D) Naive 
CD4 T cells were cultured in the presence of control Ig or PD-L1–Ig beads (with increasing amounts of PD-L1) in the presence of low levels of TGF-.  
*, P = 0.05; **, P = 0.0006; ***, P < 0.0001. Data are representative of three similar experiments. (E) Analysis of CFSE dye dilution of naive CD4+CD62L+CD25  
CD44low 2D2 Tg T cells cultured with increasing quantities of PD-L1–Ig (PD-L1 bead is coated with anti-CD3, anti-CD28, and 20, 40, or 60% PD-L1–Ig, 
respectively) or control Ig in the presence of TGF-. After 3 d of co-culture, cells were stained for Foxp3 expression. 20 U/ml of exogenous IL-2 was added 
to cultures shown on the bottom (green). Data are representative of three similar experiments. (F) Quantitative analysis of Foxp3+ T cell conversion in  
the presence or absence of IL-2 and increasing quantities of immobilized PD-L1. *, P < 0.0001 for all concentrations of PD-L1–Ig versus control Ig in the 
absence of IL-2; *, P = 0.005 and **, P = 0.0021 for 40 and 60% PD-L1–Ig, respectively, versus control Ig, in the presence of IL-2. Data are representative  
of three similar experiments. (G) Analysis of Foxp3 expression on a per cell basis, quantified via MFI. *, P = 0.0003 and **, P < 0.001, PD-L1–Ig 20% and 
PD-L1–Ig 40% versus control Ig, in the absence of IL-2; *, P = 0.03, PD-L1–Ig 60 versus control Ig, in presence of IL-2. Data represent the mean ± SD  
and are representative of more than five independent experiments with n = 3 mice per treatment condition.
 
immunity and the maintenance of self-tolerance (Keir et al., 
2007a, 2008). PD-1 is up-regulated on T cells upon activa-
tion, and its ligands have distinct expression patterns, with 
PD-L1 being expressed much more broadly than PD-L2. 
PD-L1 is constitutively expressed on mouse APCs (DCs, 
macrophages, and B cells) and T cells and is further up-regulated 
upon activation. PD-L1 is also expressed on a wide variety 
of nonhematopoietic cell types, including vascular endothe-
lial cells, pancreatic islet cells, and at sites of immune privi-
lege including the placenta, testes, and eye (Keir et al., 2008). 
In contrast, PD-L2 is inducibly expressed primarily on DCs 
and macrophages.
PD-1–PD-L interactions regulate peripheral CD4 and   
CD8 T cell tolerance at multiple checkpoints. The PD-1– 
PD-L1 pathway exerts its effects during the initial phase of 
activation and expansion of autoreactive T cells by attenu-
ating self-reactive T cell responses during presentation of   
self-antigen by DCs. For example, loss of PD-1 enhances   
the responses of naive self-reactive CD8 T cells upon en-
counter with DCs bearing self-antigen (Probst et al., 2005; 
Keir et al., 2007b). In addition, PD-L1 has a novel role   
in inhibiting self-reactive T eff cell function. Bone mar-
row chimera studies have shown that PD-L1 on nonhema-
topoietic cells mediates tissue tolerance, controlling the   
intensity of T eff cell responses in nonlymphoid organs 
and shielding tissues from potentially pathogenic effects of 
self-reactive T cells and immune-mediated tissue damage 
(Keir et al., 2006).
T reg cells are also essential for the maintenance of   
peripheral tolerance, and roles for B7-CD28 family members 
during T reg cell development are emerging. CD28 is a critical 
regulator of T reg cell homeostasis and function (Tang et al., 
2003; Liang et al., 2005). We demonstrate key roles for PD-L1 
in promoting iT reg cell development and function. Signifi-
cantly, PD-L1 can promote differentiation and maintain the 
function of induced T reg cells by sustaining and enhancing 
Foxp3 expression in iT reg cells. PD-L1 induces iT reg   
cells by inhibiting the Akt/mTOR signaling cascade, thereby 
flipping the “molecular switch” in a naive CD4+ T cell 
toward T reg cell development. The novel role for PD-L1 
in the maintenance, as well as induction of iT reg cells, iden-
tifies PD-L1 as an attractive therapeutic target for controlling 
T reg cell plasticity.
RESULTS
PD-L1 synergizes with TGF- to promote iT reg cell conversion
To investigate whether PD-L1 influences the development of 
iT reg cells, we cultured freshly isolated WT or PD-L1/ 
APCs with naive CD4+CD62LhiFoxp3.GFP T cells from 
Foxp3.GFP reporter mice in the presence of TGF- and anti-
CD3. WT APCs induced naive T cell conversion into Foxp3+ 
iT reg cells over a range of TGF- concentrations (0.5, 1, 2, 4, 
and 8 ng/ml; 39.8–42.9% CD4+Foxp3+; Fig. 1 A). In con-
trast, when naive T cells were cultured with PD-L1/ APCs, 
anti-CD3, and the same range of TGF- concentrations, we 
observed a profound defect in conversion to Foxp3+ iT reg 
cells (17.4–22.1% CD4+Foxp3+; Fig. 1 A), suggesting a critical 
role for PD-L1 in regulating T reg cell induction.
To further interrogate the role of PD-L1 in iT reg cell   
development and circumvent potentially confounding factors 
(such as surface molecules or soluble factors) that might be 
differentially expressed by WT and PD-L1/ APCs, we con-
ducted further studies using epoxy beads covalently coupled 
with anti-CD3, anti-CD28, and either PD-L1–Ig or control 
Ig as artificial APCs (henceforth referred to as PD-L1–Ig beads 
or control Ig beads). Co-culture of PD-L1–Ig beads, but not 
control Ig beads, with naive CD4+CD62LhiFoxp3 T cells 
significantly enhanced iT reg cell development in the presence 
of TGF- (58.9 vs. 32.5%; Fig. 1 B).
Because TGF- has been shown to be necessary for iT 
reg cell generation (Chen et al., 2003; Fantini et al., 2004; 
Marie et al., 2005; Pyzik and Piccirillo, 2007), we questioned 
whether PD-L1 alone could drive iT reg cell development 
and override the need for TGF-. We cultured naive T cells 
with PD-L1–Ig beads or control Ig beads in the absence of 
exogenous TGF-. PD-L1 beads alone could induce the 
conversion of naive T cells to Foxp3+ iT reg cells without 
TGF- (2.67 vs. 0.64% for control Ig bead). Moreover, even 
with increasing amounts of TGF-, we could not augment 
iT reg cell development with control Ig beads to the extent 
observed with PD-L1–Ig beads (Fig. 1 C). Very low amounts 
of TGF- (0.033–0.33 ng/ml) were sufficient for significant 
conversion of naive CD4+ T cells into iT reg cells by PD-
L1–Ig-coated beads (Fig. 1 D).
To determine the contribution of PD-L1 to iT reg cell 
development, we titered the amount of PD-L1–Ig on the 
surface of the beads and found a quantitative relationship 3018 PD-L1 promotes iT reg development and function | Francisco et al.
PD-L1 strongly inhibited overall CD4 T cell expansion and   
survival. IL-2 was critical for overcoming high-dose PD-
L1–mediated inhibition of T cell expansion and rescued   
iT reg cell development at high concentrations of PD-L1 
(PD-L1–Ig 60; Fig. 1, E–G). Using CFSE dye dilution in 
these assays, we found that PD-L1 simultaneously promoted 
the development of T reg cells and suppressed the develop-
ment and activation of T eff cells. Furthermore, PD-L1 in-
duced greater levels of Foxp3 expression per cell as indicated 
by the mean fluorescence intensity (MFI) of GFP expression 
(Fig. 1 G). Thus, PD-L1 and TGF- have synergistic roles 
in regulating Foxp3+ iT reg cell development.
PD-L1–induced CD4+Foxp3+ T reg cells suppress  
CD4+ T eff cells
To assess whether PD-L1–induced iT reg cells not only ex-
press Foxp3 but also function as suppressor T cells, we treated 
naive T cells with TGF- plus control Ig or PD-L1–Ig beads 
and sorted Foxp3.GFP+ iT reg cells after 3 d of culture. 
Sorted iT reg cells were then cultured in a standard suppres-
sion assay with CD4+CD25 responder T cells and bead-
bound anti-CD3/anti-CD28 plus PD-L1–Ig for another 3 d. 
Both PD-L1 iT reg cells and control iT reg cells could sup-
press the proliferation of WT T eff cells to a similar extent as 
that measured by [3H]thymidine incorporation (Fig. 2 A). To 
evaluate whether PD-L1 iT reg cells or control iT reg cells 
affect the suppression of T eff cell proliferation on a per cell 
basis, we performed additional suppression assays measuring 
CFSE dilution of T eff cells. We cultured either CD45.1 
PD-L1 iT reg cells or control iT reg cells with CD45.1+ T eff 
cells plus bead-bound anti-CD3/anti-CD28 and PD-L1–Ig 
for 3 d and analyzed CFSE dilution in CD45.1+ T eff cells by 
flow cytometry (Fig. 2 B). PD-L1 iT reg cells reduced T eff 
cell expansion at the single cell level to a greater extent than 
control iT reg cells (1.5-fold greater, P = 0.006), as measured 
by the division index (Fig. 2 C). These studies demonstrate 
that PD-L1 has a significant role in inducing the develop-
ment of functional Foxp3+ iT reg cells.
PD-L1 enhances and maintains Foxp3 expression on iT reg 
cell and augments suppression at low T reg/T eff cell ratios
Our studies thus far could not discriminate whether PD-L1 
only controls iT reg cell development or also has a role in 
maintaining iT reg cell function. Recent studies indicate that 
continued Foxp3 expression is necessary for sustaining T reg 
cell  function  (Kim  et  al.,  2007;  Williams  and  Rudensky, 
2007). Therefore, we investigated whether PD-L1 influences 
the maintenance of Foxp3 expression and iT reg cell suppressive 
function. We induced T reg cell development by culturing 
naive CD45.1 T cells with either PD-L1–Ig beads or control 
Ig beads plus TGF-. After 3 d of culture, PD-L1 iT reg cells 
or control iT reg cells were sorted by Foxp3.GFP+ expression 
and used in secondary cultures to evaluate the maintenance   
of Foxp3 expression and iT reg cell suppressive capacity. The 
sorted PD-L1 or control iT reg cell were cultured with 
CD4+CD25CD45.1+ T eff cells, in the presence of either 
between the amount of PD-L1 and the frequency of in-
duced Foxp3+ CD4 T cells. Greater numbers of Foxp3+ 
CD4 T cells could be induced with increasing amounts   
of PD-L1, particularly in the absence of exogenous IL-2 
(Fig. 1, E and F); however, at the highest concentration, 
Figure 2.  PD-L1–induced CD4+ Foxp3+ T reg cells suppress CD4+ T 
eff cells in vitro. (A) PD-L1 iT reg cell function was assessed by [3H]thymidine 
incorporation of naive CD4+CD25 T eff cells after 3 d of co-culture  
at a 1:1 T reg/T eff cell ratio plus PD-L1 beads (5:1 bead/T eff cell ratio). 
Data represent the mean ± SD and are representative of at least two in-
dependent experiments. (B) PD-L1 iT reg cell function was assessed by 
CFSE dilution of naive CD4+CD25 T eff cells after 3 d of incubation with 
1:1 T reg/T eff cell ratio and PD-L1 beads (5:1 bead/T eff cell ratio). Data 
represent the mean ± SD and are representative of three similar experi-
ments. (C) Quantification of T eff cell proliferation in B, analyzing the 
division index of gated CD4+CD45.1+ (the number of divisions a single cell 
has divided) by FlowJo software. Data represent the mean ± SD.JEM VOL. 206, December 21, 2009 
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findings point to a novel role for PD-L1 in regulating the   
stability of iT reg cells in the periphery.
We next tested whether the presence of PD-L1 could   
influence the efficiency of suppression by iT reg cells. Foxp3.
GFP+ iT reg cells were sorted and cultured with naive 
CD4+CD25CD45.1+ T eff cells plus either PD-L1–Ig or 
control Ig beads at a variety of iT reg/T eff cell ratios, as 
graphically depicted in Fig. 3 A (right). PD-L1–Ig enhanced 
iT reg cell suppressive function at a low T reg/T eff cell ratio 
of 1:4 (46% suppression using PD-L1 bead vs. 3% suppression 
using control bead, P = 0.0149; Fig. 4, A and B). The effect 
was less pronounced when T reg cells were more numerous, 
but PD-L1–Ig iT reg cells still showed improved suppressive 
capacity (Fig. 4 A). Because T eff cells may be directly inhibited 
by the presence of PD-L1 on beads during the suppression 
assay, we tested the suppressive capacity of PD-L1–Ig iT reg 
cells or control iT reg cells in the presence of TCR stimulation 
PD-L1–Ig beads or control Ig beads for 3 d (Fig. 3 A). Foxp3.
GFP expression was then assessed by flow cytometry. When 
iT reg cells were stimulated with control Ig beads, Foxp3 was 
better maintained in iT reg cells originally induced with PD-
L1–Ig beads as compared with control Ig beads (24.2% posi-
tive vs. 7.07% positive; Fig. 3 B, top). In addition, stimulation 
of control iT reg cells or PD-L1 iT reg cells with PD-L1–Ig 
beads significantly enhanced the percentage of iT reg cells 
maintaining Foxp3 expression (16.1% for control-iT reg cells 
vs. 38% for PD-L1 iT reg cells; Fig. 3 B, bottom). Interest-
ingly, iT reg cells that were both induced and restimulated in 
the presence of PD-L1–Ig maintained the greatest percentage 
of Foxp3-expressing cells (38%; Fig. 3, B and C). These studies 
demonstrate that PD-L1 strategically regulates Foxp3 expres-
sion in CD4 T cells at two stages: (1) during the induction 
phase of naive T cell conversion to iT reg cells and (2) during 
the effector phase of iT reg cell–mediated suppression. These 
Figure 3.  PD-L1 maintains Foxp3 expression by iT reg cells during suppression of effector cell function. (A) Schematic depiction of experiment. 
Naive CD4+CD62LhiFoxp3.GFP T cells were induced toward T reg cell differentiation for 3 d in the presence of TGF- plus IL-2 and either control or PD-L1 
beads. Foxp3.GFP+CD45.1 cells were then sorted and co-cultured with sorted CD4+CD25CD45.1+ in the presence of either control or PD-L1 beads dur-
ing the 3-d suppression assay. (B) 72 h after co-culture, CD4+CD45.1 cells were gated and analyzed for GFP expression. (C) Quantification of experiment 
depicted in B. Data represent the mean ± SD and are representative of at least two independent experiments.3020 PD-L1 promotes iT reg development and function | Francisco et al.
CD4+CD62LhiFoxp3.GFP T cells into PD-L1/PD-L2/ 
Rag/ or WT Rag/ mice and analyzed the CD4+ T 
cells for Foxp3 expression at days 14–17 after transfer by flow 
cytometry. It should be noted that PD-L1/ versus PD-
L1/PD-L2/ APCs are similarly deficient in their ability 
to induce Foxp3+ iT reg cells in the presence of TGF- and 
anti-CD3 (unpublished data). There were 10-fold fewer 
Foxp3.GFP+ cells in PD-L1/PD-L2/Rag/ recipients 
compared with WT Rag/ recipients (Fig. 5, A and B). 
These data demonstrate the critical role of PD-L in regulat-
ing the de novo generation and/or maintenance of Foxp3+   
iT reg cell in vivo. We next compared Foxp3CD4+ T 
eff cell responses in PD-L1/PD-L2/Rag/ and WT 
Rag/ recipients by measuring cytokine production by   
alone (i.e., control Ig beads) over a range of T reg/T eff cell 
ratios (Fig. 4 C). PD-L1 iT reg cells are far more effective 
than control iT reg cells at limiting the proliferative capacity 
of T eff cells at very low T reg/T eff cell ratios. Collectively, 
these results show that PD-L1 enhances the efficiency of sup-
pression by iT reg cells.
PD-L1 deficiency leads to impaired T reg cell conversion in vivo
To investigate the role of PD-L1 in iT reg cell development   
and function in vivo, we compared iT reg cell conversion   
and  function  in  Rag/  mice  because  iT  reg  cells  can 
spontaneously develop from naive T cells in a lymphope-
nic environment (Bloom et al., 2008; Calzascia et al., 2008;   
Winstead et al., 2008). We adoptively transferred naive 
Figure 4.  PD-L1 enhances the efficiency of iT reg cell–mediated suppression of T eff cells. (A) Foxp3.GFP+ iT reg cells were sorted and co-
  cultured with naive CD4+CD25CD45.1+ T eff cells plus either PD-L1–Ig beads or control Ig beads (at various T reg/T eff cell ratios). 72 h later, cultures 
were pulsed with [3H]thymidine for 12–14 h. P < 0.0009 at a 1:4 ratio cultured with PD-L1 beads (comparing T eff + iT reg vs. T eff cells). Data represent 
the mean proliferation ± SD and are representative of at least four independent experiments. (B) Quantification of suppression at 1:4 ratio of T reg/T eff 
cells. P = 0.0149. Data represent the mean ± SD and are representative of at least four independent experiments. (C) PD-L1 iT reg cells suppress T eff cells 
more effectively than control iT reg cells. CD4+CD62L+ FoxP3.GFP naive T cells were induced with PD-L1 or control beads in the presence of TGF-. GFP+ 
iT reg cells were sorted and co-cultured at the indicated T reg/T eff cell ratios with CFSE-labeled CD4+CD25 Thy1.1 T eff cells and beads coated with  
anti-CD3 and anti-CD28 (in the absence of PD-L1) for 3 d. Graphs are representative of three experimental replicates and data are representative of  
three independent experiments.JEM VOL. 206, December 21, 2009 
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Figure 5.  Attenuated iT reg cell development in PD-L1/PD-L2/ mice in vivo. (A) CD4+CD62LhiFoxp3.GFP cells were adoptively transferred  
i.v. into the tail veins of WT Rag/ or PD-L1/PD-L2/Rag/ mice. Spleens and lymph nodes were analyzed for Foxp3.GFP expression 14–17 d  
after transfer. (B) Quantitation of Foxp3.GFP expression from independent mice depicted in A. Data represent the mean ± SE of five independent mice.  
(C and D) Analysis of IL-17+ and IFN-+ T eff cells by intracellular cytokine staining (C) and ratios of IL-17–producing T eff/T reg cells and IFN-–produc-
ing T eff/T reg cells from WT Rag/ or PD-L1/PD-L2/Rag/ mice 14–17 d after transfer (D). Data represent the mean ± SD of n = 5 mice per group 
and are representative of two independent experiments.3022 PD-L1 promotes iT reg development and function | Francisco et al.
sisting of mononuclear cells and a few scattered neutrophils. 
Thus, similar to the PD-L1/PD-L2/Rag/recipients of 
naive CD4 T cells, WT Rag/ mice given anti–PD-L1 mAb 
exhibited defects in iT reg cell generation and developed pul-
monary pathology. Collectively, these studies demonstrate a 
key role for PD-L1 in iT reg cell development in vivo.
PD-L1 antagonizes the Akt–mTOR signaling cascade during 
the induction of iT reg cells
Recent studies have shown notable differences in signaling 
pathways used by CD4+ T eff cells compared with T reg 
cells. In particular, Akt signaling is essential for naive T cell   
activation  and  proliferation  but  dispensible  for  T  reg  cell   
development and function (Battaglia et al., 2006; Coenen et al., 
2007; Gao et al., 2007; Qu et al., 2007; Strauss et al., 2007; 
Haxhinasto et al., 2008; Sauer et al., 2008). These findings 
led us to hypothesize that PD-L1 may mediate T reg cell con-
version by antagonizing the Akt signaling pathway. To test 
this, we cultured naive T cells in the presence of PD-L1–Ig or 
control Ig beads for 18 h and then measured phosphorylation 
of Akt, mTOR, and S6. Intracellular staining for phospho-
Akt and phospho-mTOR revealed significantly diminished 
levels of Akt and mTOR phosphorylation when naive T cells   
were cultured in the presence of increasing quantities of   
PD-L1 relative to control Ig (MFIs of phospho-Akt and 
phospho-mTOR were significantly down-regulated; Fig. 7, 
A–D). As a downstream target of the mTOR-regulated p70 
S6 kinase, phosphorylation of S6 ribosomal protein reflects 
the sustained activation of the Akt–mTOR pathway. Upon   
culture of naive CD4 T cells with increasing amounts of 
PD-L1, we observed a marked decrease in phospho-S6 as 
compared with control (Fig. 7, E and F). Furthermore, PD-L1 
up-regulated the expression of PTEN (phosphatase and tensin 
homologue deleted on chromosome 10), a phosphoinositol 
3,4,5-triphosphatase important for antagonizing PI3K signal-
ing, demonstrating that PD-L1 antagonizes the Akt pathway 
during T reg cell differentiating conditions (Fig. 7, G and H). 
Western  blots  assessing  the  specific  down-regulation  of 
phospho-Akt, phospho-mTOR, and phospho-S6 and up-
regulation of PTEN confirmed phospho-flow cytometry 
data (unpublished data).
Down-regulation of the MAP kinase signaling cascade 
has also been implicated in TGF-–mediated T reg cell   
development (Luo et al., 2008). We questioned whether   
PD-L1 might regulate T reg cell differentiation by modulat-
ing the MAP kinase pathway. Stimulation of naive T cells 
with increasing amounts of PD-L1 Ig attenuated the phos-
phorylation of ERK2/p42 (Fig. S2). These data further sub-
stantiate  our  hypothesis  that  the  PD-L1–PD-1  pathway 
truncates signaling cascades downstream of TCR signaling, 
preferentially converting naive T cells toward a Foxp3+ T   
reg cell lineage.
DISCUSSION
In this paper, we demonstrate a novel function for PD-L1 in 
promoting the development and sustaining the function of 
Foxp3-CD4+ cells 14–17 d after naive T cell transfer. There   
were comparable numbers of IL-17 and IFN-–producing   
cells generated in PD-L1/PD-L2/Rag/ and WT Rag/  
recipients (Fig. 5 C). However, IL-17– and IFN-–producing   
T eff cells highly outnumbered the iT reg cells in PD-L1/ 
PD-L2/Rag/ recipients as a result of the paucity of iT reg 
cells in these mice (Fig. 5 D), resulting in a dramatic increase in 
the T eff/T reg cell ratio.
PD-L1/PD-L2/ Rag/ mice develop fatal  
immune-mediated pulmonary damage after  
transfer of naive CD4+Foxp3 T cells
To evaluate the in vivo consequences of the skewed T reg/T 
eff cell ratio in PD-L1/PD-L2/Rag/ recipients, we 
monitored PD-L1/PD-L2/Rag/ and WT Rag/ mice 
after transfer of CD4+CD62LhiFoxp3.GFP T cells (Fig. 6 A). 
PD-L1/PD-L2/Rag/  recipients  exhibited  rapid  and 
dramatic weight loss beginning on day 6 after transfer, with a 
reduction of 17.6 ± 5.7% (P ≤ 0.0001) of the pretransfer body 
weight within 2 wk, compared with 2.65 ± 2.7% (P = 0.100) 
weight loss in WT Rag/ recipients. There was a marked in-
crease in cellularity of the lymph nodes and spleen in PD-L1/ 
PD-L2/Rag/ compared with WT Rag/ adoptive trans-
fer recipients on days 14–17 after transfer (Fig. 6 B).
Strikingly, all PD-L1/PD-L2/Rag/ recipients were 
moribund within 17 d after transfer of naive T cells (n = 12)   
in marked contrast to the survival of all WT Rag/ recipients 
(n = 8; Fig. 6 C). In a separate experiment, we examined 
PD-L1/PD-L2/Rag/ and WT Rag/ recipients his-
tologically on days 14–17 after transfer (Fig. 6 D). The lungs 
of PD-L1/PD-L2/Rag/ recipients showed widespread 
severe  perivascular,  peribronchial,  and  interstitial  infiltrates 
consisting predominantly of mononuclear cells and some neu-
trophils. Alveolar walls were markedly thickened by the in-
flammation, and there was severe alveolar consolidation and 
edema. This potentially reduced gas exchange in these mice. 
In contrast, all the WT Rag/ recipients displayed a minimal 
degree of inflammation and absence of alveolar consolidation 
in the lungs. Both groups also showed varying degrees of mild 
colitis on days 14–17 after adoptive transfer. Analysis of brain, 
heart, pancreas, kidney, esophagus, stomach, small intestine, 
and skin revealed only mild scattered inflammation with no 
significant differences between WT and PD-L1/PD-L2/ 
Rag/ recipients (unpublished data).
To ascertain the critical role for PD-L1 in vivo, we trans-
ferred naive CD4 T cells to Rag/ recipients treated with 
anti–PD-L1 blocking antibody (Fig. S1) and monitored the 
mice for 3–4 wk. Mice were sacrificed to assess T reg cell   
development and immunopathology. A significant defect in 
de novo iT reg cell development was observed in Rag/ 
mice given anti–PD-L1 mAb compared with isotype control 
in both the spleen (isotype = 6.35% vs. anti–PD-L1 = 2.73%, 
P = 0.0318) and mesenteric lymph nodes (isotype = 30.2% vs. 
anti–PD-L1 = 18%, P = 0.0219). The lungs of Rag/ mice 
treated with anti–PD-L1 mAb showed moderate to severe 
perivascular, peribronchial, and interstitial inflammation, con-JEM VOL. 206, December 21, 2009 
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Figure 6.  Dramatic weight loss, severe pulmonary inflammation, and fatal inflammatory disorder develop in PD-L1/PD-L2/ Rag/  
mice after adoptive transfer of naive CD4+CD62LhiFoxp3.GFP T cells. Sorted CD4+CD62LhiFoxp3.GFP cells were adoptively transferred i.v. into WT 
Rag/ or PD-L1/PD-L2/ Rag/ mice. (A and B) Clinical manifestations shown are the following: percentage of weight loss of mice after adoptive 
transfer of CD4+CD62LhiFoxp3.GFP cells into WT Rag/ or PD-L1/PD-L2/Rag/ (P < 0.001; n = 5 mice per group; A) and quantified lymph node 
(axillary, brachial, and inguinal) cellularity (B). Data represent the mean ± SD and represent two independent experiments. (C) Survival of mice after adop-
tive transfer of naive CD4+CD62LhiFoxp3.GFP T cells was monitored for 30 d. PD-L1/PD-L2/ Rag/, n = 12; WT Rag/, n = 8. (D) Hematoxylin  
and eosin–stained paraffin sections of lung tissue obtained on days 14–17 after transfer of naive CD4+CD62LhiFoxp3 T cells. Bars: (top, 40×) 500 µm; 
(bottom, 400×) 50 µm. PD-L1/PD-L2/ Rag/, n = 9; WT Rag/, n = 10. Data represent more than four independent experiments.3024 PD-L1 promotes iT reg development and function | Francisco et al.
conversion of naive CD4+ T cells toward Foxp3-expressing 
cells with suppressive capacity (Chen et al., 2003; Fantini 
et al., 2004), PD-L1 could induce T reg cells in the absence 
of exogenous TGF-, suggesting that PD-L1 signaling alone 
can serve to promote iT reg cell development. Our signaling 
studies support the conclusion that PD-L1 reduces signaling 
of the Akt–mTOR pathway in naive T cells, which is critical 
iT reg cells. There was a profound defect in conversion of 
naive CD4 T cells into Foxp3+ iT reg cells in the absence of 
PD-L1. Consistent with this observation, PD-L1 presented 
on beads (along with anti-CD3 and anti-CD28) could induce 
the development of functional Foxp3+ iT reg cells, demon-
strating that PD-L1 is responsible for promoting iT reg cell 
development. Although TGF- signaling is important for the 
Figure 7.  PD-L1 regulates T reg cell development by antagonizing the Akt–mTOR signaling cascade. (A, C, F, and G) Phospho-Akt, phospho-
mTOR, PTEN, and phospho-S6 analysis at 18 h after culture with control Ig bead (hIgG = 60% of bead surface, with remaining surface coated with anti-
CD3 and anti-CD28) or various titers of PD-L1–Ig bead (PD-L1–Ig 20, 40, 60 = 20, 40, and 60% of bead surface coated with PD-L1–Ig, with remaining 
surface coated with anti-CD3 and anti-CD28 plus control Ig). (B, D, E, and G) MFI analysis of phospho-Akt (B; *, P = 0.001; **, P = 0.003; and ***, P = 
0.0008, at 20, 40, and 60% PD-L1, respectively, compared with control Ig), phospho-mTOR (D; *, P = 0.0064; and **, P = 0.0001, at 20 and 60% PD-L1, 
respectively, compared with control Ig), phospho-S6 (E; P = 0.0012, P = 0.0007, and P = 0.0002, at 20, 40, and 60% PD-L1, respectively, compared with 
control Ig), and PTEN (H; *, P = 0.0378, PD-L1–Ig 40 compared with control Ig) at 18 h. n = 3 mice per experiment, representative of three experiments. 
Data are representative of the MFI ± SD and are representative of three experiments.JEM VOL. 206, December 21, 2009 
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in limiting the function of exhausted CD8 T cells (Barber   
et al., 2006; Sharpe et al., 2007). PD-L1 blockade reinvigorates 
the function of these T cells and enhances viral clearance. 
Thus, PD-L1 may exert inhibitory effects in chronic infec-
tions by promoting iT reg cell development and maintaining 
iT reg cell function, as well as by inhibiting anti-microbial   
T eff cell function.
PD-L1/PD-L2/Rag/ recipients of Foxp3 naive 
T cells resemble scurfy mice, which have a deficit in Foxp3 
and die by 3 wk of age as a result of multiorgan infiltration of   
CD4+CD8 T cells (Clark et al., 1999; Brunkow et al., 2001; 
Schubert et al., 2001). PD-L1/PD-L2/Rag/ recipients 
had a marked deficit in Foxp3+ T reg cell development, alter-
ing the T reg/T eff cell ratio. These findings illustrate the im-
portant role of PD-L1 in regulating the dynamic balance   
between T eff and T reg cells in vivo. PD-L1 may do the   
following: (a) control T reg cell development in lymphoid   
organs, which is important for immune homeostasis; (b) promote 
T reg cell development at target tissues, protecting against 
immune-mediated tissue damage, and (c) sustain and enhance   
T reg cell function within an inflammatory microenviron-
ment, effectively counterbalancing the pathogenic T eff cells.
Foxp3 is a transcription factor only expressed in the T reg 
cell lineage (Fontenot et al., 2003; Hori et al., 2003; Vignali 
et al., 2008). Along with contributing a distinct genetic sig-
nature to T reg cells, Foxp3 conveys regulatory activity to nT 
reg cells, iT reg cells, and, upon ectopic expression, in con-
ventional T cells (Schubert et al., 2001; Fontenot et al. 2003, 
2005; Hori et al., 2003; Gavin et al., 2007; Hill et al., 2007). 
PD-L1 can induce and maintain the expression of Foxp3 in 
iT reg cells, suggesting that PD-L1 may function to stabilize 
and sustain T reg cell function in the periphery, similar to   
effects reported for TGF- (Marie et al., 2005; Pyzik and 
Piccirillo, 2007). This maintenance of Foxp3 expression may 
explain both the increased efficiency of suppression seen   
for T reg cells cultured with PD-L1 and the lack of T reg   
cell conversion in the PD-L1/PD-L2/Rag/ adoptive 
transfer recipients. It has been suggested that although Foxp3 
expression is a salient feature of the regulatory cell signature, 
it  is  not  the  master  regulator  of  T  reg  cell  development 
(Ramsdell, 2003; Collison et al., 2007; Hill et al., 2007). In 
fact, it is increasingly clear that other factors (such as TGF- 
and IL-2; Ramsdell, 2003; Setoguchi et al., 2005) induce key 
changes within the regulatory cell transcriptome that contribute 
to the identity of T reg cells separate from, and in addition to, 
the effects attributed to Foxp3 (Lin et al., 2007). In vivo, 
TGF- production is maintained at a basal level and up-
regulated with inflammation. Interestingly, endogenous TGF- 
was not sufficient to induce and/or maintain Foxp3+ iT reg 
cells in PD-L1/PD-L2/ Rag/ recipients. In comple-
mentary studies, PD-L1 blockade similarly impaired iT reg   
cell development in vivo, showing that loss of PD-L1 can   
diminish the effect of TGF-, which is critical for iT reg cell 
identity and function. This indicates that PD-L1 contributes 
unique and essential signals that drive iT reg cell development 
and function.
for their conversion into iT reg cells. Furthermore, we show 
that PD-L1 has a novel role in sustaining expression of Foxp3 
in iT reg cells and in enhancing iT reg cell suppressive func-
tion. Thus, these studies reveal a new mechanism by which 
PD-L1 mediates T cell tolerance. PD-L1 can inhibit self-
reactive T cell responses by promoting iT reg cell development 
and maintaining iT reg cell function.
Where does PD-L1 exert its critical effects on iT reg cell 
development and function? PD-L1 is widely expressed on   
hematopoietic and nonhematopoietic cells (Keir et al., 2008). 
There may be a critical interaction between PD-L1 expressing   
DC and T cells during the induction of T reg cell development 
from naive T cells (Brown et al., 2003). PD-L1 is also expressed 
on T cells; however, WT T cells transferred into PD-L1/PD-
L2/ Rag/ recipients could not convert to iT reg cells, sug-
gesting that T cell–T cell interaction via PD-L1 is not sufficient 
to drive naive T cell conversion. Instead an interaction with the 
host environment is crucial for T reg cell conversion.
Our bone marrow chimera studies have demonstrated   
an important role for PD-L1 on nonhematopoietic cells in 
mediating tissue tolerance (Keir et al., 2006). Our findings of 
critical roles for PD-L1 in the development and maintenance 
of iT reg cell function suggest that PD-L1 may protect tissues 
from the potentially pathogenic self-reactive T eff cells not 
only by inhibiting the function of T eff cells but also by   
increasing the frequency and function of T reg cells in the 
target tissue. By promoting de novo generation of iT reg cells 
in situ, PD-L1 may play a role in mediating immune privilege, 
especially in environments where TGF- is present (e.g., 
placenta and eye).
PD-L1 may also exert its inhibitory effects on anti-tumor 
and anti-microbial immunity, at least in part by inducing   
T reg cell development and sustaining iT reg cell function. 
PD-L1 is expressed on a wide variety of tumors, and high 
levels of PD-L1 expression strongly correlate with unfavorable   
prognosis in several cancers (Dong et al., 2002; Iwai et al., 
2002; Strome et al., 2003; Konishi et al., 2004; Thompson   
et al., 2004; Blank et al., 2005; Hirano et al., 2005; Ohigashi 
et al., 2005; Dorfman et al., 2006; Wu et al., 2006; Inman et al.,   
2007; Nakanishi et al., 2007; Nomi et al., 2007; Zhang et al., 
2008). The numbers of Foxp3+ T cells within tumors also 
correlates with a poor prognosis. Our work provides a mech-
anism by which high PD-L1 expression can lead to increased 
numbers of Foxp3+ T reg cells and thus, poor prognosis. 
Increased PD-L1 expression by tumor cells may induce and 
maintain iT reg cells in the periphery, thereby augmenting 
the suppression of anti-tumor T cell responses and allowing 
tumor progression.
Increased T reg cells are also seen during chronic in-
fections (Belkaid, 2008), correlating with a lack of sterilizing 
immunity. During persistent infection by Helicobacter pylori, 
PD-L1 is up-regulated on gastric epithelial cells (Das et al., 
2006). Blocking PD-L1 on gastric epithelial cells enhances 
CD4 T eff cell function and prevents the generation of 
CD4+CD25hiFoxp3+ T reg cells in vitro (Beswick et al., 
2007). During chronic viral infections, PD-L1 has a key role   3026 PD-L1 promotes iT reg development and function | Francisco et al.
a FACSAria cell sorter (BD). Cell surface staining was performed at 4°C   
in FACS Buffer (1% FCS, PBS, 2 mM EDTA; Invitrogen). CFSE was   
purchased from Invitrogen.
Cell purification. Naive CD4+CD62L+Foxp3.GFP T cells were isolated 
from the spleen and lymph nodes (axillary, brachial, and inguinal) of male 
C57BL/6 Foxp3.GFP or 2D2 Foxp3.GFP reporter mice. Single cell suspen-
sions were made by mechanical dissociation. After red blood cell lysis with 
ACK buffer (Invitrogen), cells were washed and isolated by incubation with 
CD4 microbeads, positively selected through LS columns (Miltenyi Biotec), 
and stained with anti-CD4 PerCP-Cy5.5 (clone RM4-5; eBioscience) and 
anti-CD62L APC (clone MEL-14; eBioscience) before cell sorting on a 
FACSAria cell sorter. Naive CD4+CD62L+Foxp3.GFP T cells were always 
>99.2% pure.
In vitro iT reg cell development. Anti-CD3 (clone 2C11; Bio X Cell)   
plus anti-CD28 (clone 37.51; Bio X Cell) were covalently attached to   
Dynabeads M450 glycidyl ether beads according to the manufacturer’s direc-
tions (Invitrogen). We ensured equal loading of proteins during preparation 
by keeping constant the total amount of protein (antibodies and fusion   
proteins) at 5 µg per 107 beads as previously described (Broeren et al., 2000; 
Riley et al., 2002). In general, 107 beads were coated with 1 µg of anti-CD3 
(20% of total protein), 1 µg of anti-CD28, and either 60% control human 
IgG1 (referred to control Ig beads; Bio X Cell) or 40% PD-L1-hIgG1 Fc   
fusion protein (referred to as PD-L1–Ig beads 40; R& D Systems) plus 20% 
control human IgG1 Fc. In some experiments, increasing amounts of PD-L1–Ig 
was used to coat the epoxy beads (20, 40, and 60% of total protein per 107 
beads = 1, 2, and 3 µg of PD-L1–Ig per 107 beads). In these cases, the remain-
ing surface of the beads were coated with control human IgG1. Covalent   
attachment of the proteins to the beads was performed in NaPO4 buffer for 
24 h at room temperature on a Nutating Mixer (Lab-Tech Incorporated). 
Beads were then washed three times in PBS over a magnetic column and re-
suspended in complete media before use.
CD4+CD62L+Foxp3 naive T cells were cultured with beads at a fixed 
ratio of 1:5 (T cells/beads). In brief, 1–2 × 106 T cells were plated at 106/ml   
in a 24-well flat-bottom tissue culture plate with beads in complete media   
consisting of RPMI-1640 with L-glutamine (Invitrogen) supplemented   
with 10% FCS (Sigma-Aldrich), penicillin-streptomycin (100 U penicillin and 
100 µg streptomycin; Invitrogen), 12 mM HEPES (Invitrogen), and 50 µM   
-mercaptoethanol (Sigma-Aldrich) plus 2 ng/ml TGF- (R&D Systems) and 
20 U/ml rh-IL2 (R&D Systems) for 3 d at 37°C with 5% CO2. In some   
experiments, sorted CD4+CD25CD62L+CD44low naive T cells were labeled 
with 1 µM CFSE before culture with beads and TGF- for 3 d at 37°C with 
5% CO2. T cells were then stained for Foxp3 expression (eBioscience). To fur-
ther evaluate the effect of IL-2 on PD-L1–mediated T reg cell development, 
some experiments were conducted in the absence of exogenous rh-IL2 (as noted 
in the Fig. 1 legend). To analyze the effect of TGF- on PD-L1–mediated   
T reg cell development, we performed some experiments using a range of 
TGF- concentrations (0.033–8 ng/ml).
In some experiments, APCs were isolated from WT or PD-L1-/- mice. 
In brief, T cells were depleted from spleens of WT or PD-L1/ mice with 
CD4 and CD8 microbeads (Miltenyi Biotec). Remaining splenocytes were   
irradiated and co-cultured with naïve CD4+CD62L+Foxp3.GFP T cells plus 
anti-CD3 and a range of TGF- concentrations (0.5–8 ng/ml).
In vitro suppression assays. Naive T cells were induced toward T reg cell 
development in vitro using PD-L1 or control beads in the presence of 20 U/ml 
TGF- and IL-2 (R&D Systems) for 3 d, at which time Foxp3.GFP+ T cells 
were sorted on a FACSAria (BD) cell sorter. Foxp3.GFP+ iT reg cells were 
then co-cultured with sorted CD4+CD25CD45.1+ naive T eff cells and 
stimulated with PD-L1 beads (containing anti-CD3 (20%), anti-CD28 (20%), 
PD-L1–Ig (40%), and control Ig (20%) for 3 d. Proliferation of T cells was   
determined by incorporation of [3H]thymidine (1 µCi/well) for 12–14 h.   
Suppression assays were performed using a constant number of T eff cells (105) 
and by addition of decreasing numbers of Foxp3.GFP+ iT reg cells plus a 5:1 
We find that PD-L1 attenuates the Akt signaling pathway 
during the conversion of naive T cells to T reg cells by reduc-
ing the phosphorylation of Akt and its downstream substrates 
mTOR  and  S6  while  simultaneously  augmenting  PTEN. 
Previous work has shown that truncation of TCR signaling 
and inhibition of the Akt–mTOR signaling axis is critical for 
T reg cell development (Qu et al., 2007; Strauss et al., 2007; 
Haxhinasto et al., 2008; Long and Buckner, 2008; Sauer   
et al., 2008). In these studies, drug inhibitors (FK506, rapa-
mycin) or retrovirally modified Akt were used to demon-
strate the role of Akt and mTOR in T reg cell development. 
We provide the first demonstration of a naturally occurring 
protein that can inhibit the Akt–mTOR cascade and regulate 
the development of T reg cells.
Similar to the Akt–mTOR pathway, recent data indicate 
an important role for the MAP kinase cascade in iT reg cell   
development (Adler et al., 2007; Huber et al., 2008; Luo   
et al., 2008). We found that PD-L1 attenuated the phosphoryla-
tion of p42/ERK2, suggesting that PD-L1 may mediate the 
induction of T reg cells by modulating ERK2 activity and, 
hence, the MAP kinase signaling cascade. No discernable   
effects of PD-L1–Ig on p38 were detected (unpublished data).
There is great interest in generating T reg cells ex vivo as 
a therapy for autoimmune diseases and transplant rejection 
(Roncarolo and Battaglia, 2007). However, recent studies   
indicate that T reg cells exhibit functional plasticity and can 
produce proinflammatory cytokines at the site of inflamma-
tion (Joetham et al., 2008; Yang et al., 2008). Thus, in order 
for T reg cell therapy to be a viable approach, it is critical to 
find ways to maintain and enhance the suppressive function 
of T reg cells. Our work suggests that administration of PD-
L1–Ig or PD-1 agonists may harness the therapeutic potential 
of iT reg cells by providing a novel means of sustaining and 
enhancing their function in vivo while concomitantly sup-
pressing the expansion and functions of activated T eff cells.
MATERIALS AND METHODS
Mice. 6–8-wk-old WT C57BL/6 and CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) 
mice were purchased from The Jackson Laboratory. PD-L1/PD-L2/ 
(Keir et al., 2006) and PD-L1/ (Latchman et al., 2004) mice were gener-
ated in our laboratory. 2D2 TCR Tg mice Foxp3-IRES-GFP knockin mice 
(Foxp3.GFP; Bettelli et al., 2006) were generated in our laboratory by cross-
ing 2D2 TCR Tg mice (Bettelli et al., 2003) with Foxp3.GFP reporter mice. 
PD-L1/PD-L2/ Rag 2/ mice were generated by breeding PD-L1/ 
PD-L2/ with Rag 2/ mice (B6.129S6-Rag2tm1Fwa N12; Taconic). Geno-
types were verified by PCR and flow cytometry. Harvard Medical School is 
accredited  by  the  American  Association  of  Accreditation  of  Laboratory   
Animal Care. Mice were maintained in a pathogen-free facility and used   
according to the Harvard Medical School Standing Committee on Animals and 
National Institutes of Health Animal Care Guidelines. Animal protocols were 
approved by the Harvard Medical School Standing Committee on Animals.
Reagents. The following anti–mouse antibodies were used in cell surface 
staining, intracellular cytokine staining, and epoxy bead conjugation: anti-
CD16/CD32 (Fc Block), CD4 PerCP-Cy5.5 (clone RM4-5), CD62L PE 
(clone MEL-14), IL-2 APC (clone JES6-5H4; eBioscience), CD45.1 APC 
(clone A20), IL-17 PE (clone TC11-18H10), and IFN- PE (clone XMG1.2; 
BD). Anti-CD3 (clone 2C11) plus anti-CD28 (clone 37.51) were used for 
bead conjugation and were purchased from Bio X Cell. Cells were sorted on JEM VOL. 206, December 21, 2009 
Article
3027
being washed with 1% FCS/PBS (incubation buffer). Cells were blocked   
with  10%  FCS/PBS  for  10  min  at  room  temperature  and  subsequently 
stained with the antibodies listed in this section for 1 h at room temperature. 
After incubation, cells were washed four times with incubation buffer and 
brought up in PBS before analysis.
Statistical analysis. Statistical analysis of Foxp3+ T reg cell development,   
T eff cell proliferation, intracellular cytokine production, and phospho–flow 
cytometry was performed using Student’s t tests in StatView (SAS Institute 
Inc). PD-L1–Ig titration, TGF- titration, and percentage of weight loss 
were analyzed by ANOVA using StatView. Prism (GraphPad Software, Inc.) 
was used for Log-rank tests comparing WT Rag/ and PD-L1/PD-
L2/ Rag/ survival after transfer of naive T cells. P-values <0.05 were 
considered statistically significant.
Online supplemental material. Fig. S1 shows that blockade of PD-L1   
attenuates T reg cell development in vivo. Fig. S2 shows that PD-L1–Ig 
attenuates  the  MAPK  signaling  pathway  during  iT  reg  cell  differen-
tiation.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20090847/DC1.
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